Hair growth control by immunosuppression.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 8818191)

Published in Arch Dermatol Res on June 01, 1996


R Paus1, J A Böttge, B M Henz, M Maurer

Author Affiliations

1: Department of Dermatology, Virchow Hospital, Humboldt-Universität zu Berlin, Germany.

Articles by these authors

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10

EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86

CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70

The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10

A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92

Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17

Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10

Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85

Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84

Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med (1998) 1.84

Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78

EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65

Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65

Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57

How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55

C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55

EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55

Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52

How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51

Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48

Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44

A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42

Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40

The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39

[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38

Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35

NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33

Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31

p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29

EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28

Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27

A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25

Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25

Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24

Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21

p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19

Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16

Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14

Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13

Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12

Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11

Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09

Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09

Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08

The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06

Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06

Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04

Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04

Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04

Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03

Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02

Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02

Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01

Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01

Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy (2009) 1.00

Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med (1997) 1.00

PLUSH TACSY: Homonuclear planar TACSY with two-band selective shaped pulses applied to C(α),C' transfer and C (β),C (aromatic) correlations. J Biomol NMR (1996) 0.99

A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol (2000) 0.99

Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98

Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics (1991) 0.98

Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97

Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97

Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97

Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97

Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97

The role of innate immunity in asthma: leads and lessons from mouse models. Allergy (2007) 0.96

Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96

Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96

Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol (2003) 0.95

EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy (2012) 0.95

Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95

Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94

Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy (2010) 0.94

Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther (2004) 0.94

The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol (2009) 0.94

Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94

Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94

Planar embryos have poor prognosis in terms of blastocyst formation and implantation. Reprod Biomed Online (2012) 0.94

Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93

Hair cycle-dependent changes in adrenergic skin innervation, and hair growth modulation by adrenergic drugs. J Invest Dermatol (1999) 0.93

Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93

Coccidioidomycosis in Tulare County, California, 1991: reemergence of an endemic disease. J Med Vet Mycol (1998) 0.92

A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol (2013) 0.92

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia (2012) 0.92

Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med (1998) 0.92

Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92

Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy (2008) 0.92

Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91

Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91

Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res (1995) 0.91